Depressive Disorder News and Research RSS Feed - Depressive Disorder News and Research

FDA approves MagVenture MagVita TMS Therapy system for treatment of Major Depressive Disorder

FDA approves MagVenture MagVita TMS Therapy system for treatment of Major Depressive Disorder

On July 31, 2015 the US Food and Drug Administration cleared the MagVita TMS Therapy system for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. [More]
Physicians may now have tools to predict people at greater risk of attempting suicide

Physicians may now have tools to predict people at greater risk of attempting suicide

People being treated for bipolar disorder and other psychiatric illnesses are at greater risk of attempting suicide, but physicians may now have tools to predict which of those individuals will attempt it and intervene early to prevent such tragedies from occurring. [More]
Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients. [More]
Aerobic exercise can help reduce excessive daytime sleepiness among depressed people

Aerobic exercise can help reduce excessive daytime sleepiness among depressed people

Aerobic exercise can help alleviate excessive daytime sleepiness among depressed individuals, researchers with UT Southwestern Medical Center's Center for Depression Research and Clinical Care have found. [More]
FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label. [More]
Current psychotherapy treatments less than optimal for war veterans suffering from PTSD

Current psychotherapy treatments less than optimal for war veterans suffering from PTSD

Our nation's veterans continue to suffer emotional and psychological effects of war—some for decades. And while there has been greater attention directed recently toward post-traumatic stress disorder (PTSD), and more veterans are seeking help, current psychotherapy treatments are less than optimal, according to a new narrative review published in the August 4, 2015 issue of JAMA. [More]
IUPUI researchers receive NIH grant to study effect of depression treatment on cardiovascular disease

IUPUI researchers receive NIH grant to study effect of depression treatment on cardiovascular disease

Indiana University-Purdue University Indianapolis researchers led by Jesse Stewart of the School of Science, have received a $2.6 million grant from the National Institutes of Health to conduct the first randomized controlled trial to determine whether depression treatment can help prevent the development of cardiovascular disease. [More]
Study reveals potential new therapeutic target for depression treatment

Study reveals potential new therapeutic target for depression treatment

Increasing the levels of a signaling molecule found in the brain can positively alter response to stress, revealing a potential new therapeutic target for treatment of depression, UT Southwestern Medical Center researchers said. [More]

New research shows that pupil response can predict child's risk of depression

How much a child's pupil dilates in response to seeing an emotional image can predict his or her risk of depression over the next two years, according to new research from Binghamton University. [More]
Virtual human helps veterans with PTSD, people with mental illness build job interview skills

Virtual human helps veterans with PTSD, people with mental illness build job interview skills

Finding a job is difficult for veterans with posttraumatic stress disorder (PTSD) and individuals with severe mental illness, who have high unemployment rates even though many want to work. [More]
Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden. [More]
New depression treatment from Magstim to be exhibited at Royal College of Psychiatry International Congress 2015

New depression treatment from Magstim to be exhibited at Royal College of Psychiatry International Congress 2015

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, will be showing its Magstim Rapid2 Therapy System at the Royal College of Psychiatry International Congress 2015 in Birmingham, UK, 29th June-2nd July. [More]
Recurrent major depression may increase osteoporosis risk in men

Recurrent major depression may increase osteoporosis risk in men

A recent study from the University of Eastern Finland in collaboration with Deakin University, Australia, shows that recurrent major depressive disorder (MDD) in men is associated with lower bone density. The use of antidepressants was also associated with lower bone mineral density (BMD), but this association was dependent on the person's weight and site of bone measurement. [More]
People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries. [More]
Emotion regulation distinguishes unipolar and bipolar depression

Emotion regulation distinguishes unipolar and bipolar depression

Patients with bipolar disorder regulate their emotions differently from those with major depressive disorder in both depressed and remitted states, a study shows. [More]
Greater evidence-based help needed for depressed workers - New report from The Work Foundation

Greater evidence-based help needed for depressed workers - New report from The Work Foundation

A report from Lancaster University’s Work Foundation recommends that in order to improve both productivity and health and wellbeing among those of working age, more concerted action must be taken to support people with depression to stay in and to return to work... [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study. [More]
Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment. [More]
WHO and UNHCR jointly issue new guide to better identify, manage mental health needs

WHO and UNHCR jointly issue new guide to better identify, manage mental health needs

Worldwide close to 80 million people are currently impacted by humanitarian emergencies arising from natural disasters and armed conflicts, such as those in the Central African Republic, South Sudan, Syrian Arab Republic, Yemen, and more recently, Nepal. WHO estimates 5% to 10% of these people suffer from a mental health condition such as depression as a result of the emergency. [More]
Advertisement
Advertisement